Mission Wealth Management LP Acquires 26 Shares of Eli Lilly and Company (NYSE:LLY)

Mission Wealth Management LP lifted its position in Eli Lilly and Company (NYSE:LLY) by 0.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,213 shares of the company’s stock after acquiring an additional 26 shares during the quarter. Mission Wealth Management LP’s holdings in Eli Lilly and Company were worth $4,204,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in LLY. PDS Planning Inc increased its stake in Eli Lilly and Company by 1.7% during the 3rd quarter. PDS Planning Inc now owns 4,975 shares of the company’s stock worth $2,672,000 after buying an additional 83 shares during the period. Boyd Watterson Asset Management LLC OH lifted its stake in shares of Eli Lilly and Company by 1.5% in the 3rd quarter. Boyd Watterson Asset Management LLC OH now owns 12,141 shares of the company’s stock worth $6,521,000 after acquiring an additional 180 shares during the period. Cavalier Investments LLC increased its holdings in Eli Lilly and Company by 67.8% during the 3rd quarter. Cavalier Investments LLC now owns 3,881 shares of the company’s stock valued at $2,085,000 after acquiring an additional 1,568 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in Eli Lilly and Company by 2.2% during the third quarter. Commonwealth Equity Services LLC now owns 337,104 shares of the company’s stock valued at $181,069,000 after buying an additional 7,254 shares in the last quarter. Finally, LFA Lugano Financial Advisors SA bought a new stake in shares of Eli Lilly and Company in the third quarter worth $60,000. 82.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on LLY. Bank of America lifted their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Morgan Stanley lifted their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. The Goldman Sachs Group upped their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Finally, Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $731.55.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY traded up $43.90 on Tuesday, reaching $781.10. 7,428,656 shares of the company’s stock were exchanged, compared to its average volume of 3,071,009. The company has a market capitalization of $742.17 billion, a price-to-earnings ratio of 134.43, a PEG ratio of 1.60 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The company has a fifty day moving average of $760.89 and a 200-day moving average of $668.00. Eli Lilly and Company has a twelve month low of $392.26 and a twelve month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same quarter in the previous year, the firm posted $2.09 earnings per share. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. On average, research analysts predict that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.